Wockhardt Shares Rally 8%, Extend Monthly Gains to 45%

Wockhardt shares surged over 8% on June 18, hitting an intraday high of ₹1,867.90, as the pharma stock continues its strong upward momentum. The stock has now rallied nearly 45% over the past month, making it one of the standout performers in the pharmaceutical sector.

High Trading Volumes Fuel the Rally

The sharp rise in Wockhardt’s stock price came on the back of heavy trading volumes, reflecting strong investor interest. Over 35 lakh shares worth nearly ₹640 crore were traded in just the first three hours on June 18, well above the stock’s 10-day average volume.

This surge in volumes points to growing market optimism around Wockhardt’s near-term prospects.

Touches 52-Week High, Then Recovers Again

Wockhardt shares had earlier touched a 52-week high of ₹1,868.80 on June 12. While the stock experienced some correction in the sessions that followed, it bounced back sharply on June 18, supported by strong fundamentals and investor confidence.

Zaynich Antibiotic in Focus

One of the major drivers behind the stock’s performance is investor anticipation around Zaynich, a breakthrough antibiotic being developed by Wockhardt to combat drug-resistant infections.

Earlier this month, the company confirmed plans to file a New Drug Application (NDA) for Zaynich with the US FDA in Q2 of FY25.

“There is a very high certainty that we should be able to market the product in the US by 2026-27,” said Chairman Habil Khorakiwala at an event celebrating 25 years of Wockhardt’s listing on the NSE.

He also added that Indian regulatory approval is expected by early next year, with the product likely to hit the domestic market by mid-2026.

Financial Turnaround in Q4FY25

Wockhardt’s recent stock momentum is also backed by improving financials. In Q4FY25, the company’s net loss narrowed to ₹45 crore, a significant improvement from the ₹177 crore loss a year ago.

• Revenue rose 6% YoY to ₹743 crore, compared to ₹700 crore in Q4FY24.

• The company posted a positive EBITDA of ₹64 crore, a dramatic turnaround from an EBITDA loss of ₹103 crore in the same quarter last year.

This return to positive operating margins signals a recovery in performance and better cost management.

What’s Next for Wockhardt?

With Zaynich’s launch timeline now becoming clearer, and the company showing strong signs of operational recovery, investors appear optimistic about Wockhardt’s growth story. The stock remains in focus for both retail and institutional players looking for exposure in the pharmaceutical innovation space.

Know more about us-
NiftyTrader
GiftNifty
BSE Option Chain
NSE Option Chain
IPO